These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 803363

  • 1. Treatment of plasma cell myeloma with cytotoxic agents.
    Bergsagel DE, Pruzanski W.
    Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
    [Abstract] [Full Text] [Related]

  • 2. Correlation of abnormal immunoglobulin with clinical features of myeloma.
    Arch Intern Med; 1975 Jan; 135(1):46-52. PubMed ID: 1111470
    [Abstract] [Full Text] [Related]

  • 3. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [Abstract] [Full Text] [Related]

  • 4. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
    Matzner Y, Benbassat J, Polliack A.
    Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296
    [No Abstract] [Full Text] [Related]

  • 5. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Drug - resistant multiple myeloma. A trial with the M 2 cyclic alkylating agent polychemotherapy.
    Buonanno G, Tortarolo M, Valente A, Castaldo C, Russolillo S, Gonnella F.
    Haematologica; 1978 Feb; 63(1):45-55. PubMed ID: 417971
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [IgM myeloma].
    Assaf ME, Pizzolato MA, De María HE, Gasparini S, Burucua JE.
    Sangre (Barc); 1983 Feb; 28(5):642-7. PubMed ID: 6420914
    [No Abstract] [Full Text] [Related]

  • 11. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)].
    Saporta L, Hugon C, Rondier J, Bontoux D, Delbarre F.
    Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 13. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
    Kyle RA, Gailani S, Seligman BR, Blom J, McIntyre OR, Pajak TF, Holland JF.
    Cancer Treat Rep; 1979 Aug 15; 63(8):1265-9. PubMed ID: 476704
    [Abstract] [Full Text] [Related]

  • 14. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE, Cowan DH, Hasselback R.
    Can Med Assoc J; 1972 Nov 04; 107(9):851-5. PubMed ID: 4653931
    [Abstract] [Full Text] [Related]

  • 15. [Pleural effusion as a first sign of Ig D lambda multiple myeloma].
    Maachi M, Fellahi S, Diop ME, Francois T, Capeau J, Bastard JP.
    Ann Med Interne (Paris); 2003 Feb 04; 154(1):70-2. PubMed ID: 12746663
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Multiple myeloma and acute leukemia associated with alkylating agents.
    Kyle RA, Pierre RV, Bayrd ED.
    Arch Intern Med; 1975 Jan 04; 135(1):185-92. PubMed ID: 1053891
    [Abstract] [Full Text] [Related]

  • 18. [Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].
    Martín Reyes G, García González I, Alférez MJ, Martínez González JM, Frutos MA.
    Nefrologia; 2001 Jan 04; 21(2):213-6. PubMed ID: 11464657
    [Abstract] [Full Text] [Related]

  • 19. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N, Lurie P, Mietlowski WL, Schilling A, Bennett JM, Horton J.
    Cancer Treat Rep; 1982 Jun 04; 66(6):1273-7. PubMed ID: 7044535
    [Abstract] [Full Text] [Related]

  • 20. Clinical classification of plasma cell myeloma.
    Conklin R, Alexanian R.
    Arch Intern Med; 1975 Jan 04; 135(1):139-43. PubMed ID: 1111462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.